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9 Abstract
10 Objective Regulatory approval of biosimilar versions of orig-
11 inator biotherapeutics requires that new biological products be
12 highly similar to originator products, with no clinically mean-
13 ingful differences in safety, purity, and potency. In some trials
14 of biosimilars of tumor necrosis factor inhibitors for the treat-
15 ment of rheumatoid arthritis (RA) and plaque psoriasis (PsO),
16 pre-specified margins for efficacy and safety have been met, but
17 differences in treatment responses between pivotal originator
18 trials and biosimilar trials have been noted. The objective of this
19 systematic review was to examine these differences.
20 Methods Searches were conducted to identify comparative
21 randomized clinical trials of approved or proposed
22 biosimilars of adalimumab, etanercept, and infliximab.
23 Results Of 83 publications identified, 16 publications were
24 included for analysis (RA: originators, n = 5; biosimilars, n = 6;
25 PsO: originators, n = 2; biosimilars, n = 3). American College
26 of Rheumatology 20% response rates were higher among
27patients with RA receiving originator biologics and biosimilars
28in biosimilar trials than among patients receiving the originator
29biologics in pivotal trials. In etanercept studies in PsO, a dif-
30ference was observed in Psoriasis Area and Severity Index 75%
31response rates between biosimilar and pivotal trials. Insufficient
32efficacy data were available from adalimumab and infliximab
33biosimilar studies in PsO to determine any differences in treat-
34ment responses between pivotal and biosimilar studies.
35Conclusions Observed differences in treatment response rates
36between pivotal originator trials and trials of originator bio-
37logics and their respective biosimilars may be attributable to
38fundamental differences in study design and/or baseline patient
39characteristics, which require further analysis.
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Key Points 43
45
6
47Biosimilarity between originator and biosimilar
48tumor necrosis factor inhibitors for the treatment of
49rheumatoid arthritis and plaque psoriasis has been
50demonstrated, but differences in treatment responses
51and safety outcomes between pivotal originator trials
52and recent biosimilar trials have been noted.
53This systematic literature review comparing pivotal
54originator biologic trials with head-to-head trials of
55originator biologics and biosimilars indicates an
56overall similarity in baseline characteristics between
57the two types of studies, yet identifies some
58differences in responses to treatment.
59The reasons for the noted differences in both efficacy
60and safety between the pivotal trials of originators
61and their respective biosimilars are currently only
62speculative. 3
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65 1 Introduction
66 Regulatory approval of biosimilar versions of originator
67 biotherapeutics requires that new biological products be
68 highly similar to originator products, with no clinically
69 meaningful differences in safety, purity, and potency [1, 2].
70 Head-to-head comparison with the originator product is
71 required at all stages of the biosimilar development pathway.
72 Analytical studies establish high similarity, followed by pre-
73 clinical and clinical studies to demonstrate the same level of
74 efficacy and safety already established for the originator
75 product. A phase I and a phase III clinical study can be
76 sufficient to achieve regulatory approval for biosimilars [3].
77 Pre-specified margins for equivalence in efficacy supporting
78 biosimilarity have been met in comparative trials of
79 biosimilars of tumor necrosis factor inhibitors (TNFis) in
80 rheumatoid arthritis (RA) [4–9] and plaque psoriasis (PsO)
81 [10–12], but differences in treatment responses and safety
82 outcomes between pivotal originator trials [13–19] and
83 recent biosimilar trials [4–12] have also been noted. The
84 objective of this systematic review was to examine differ-
85 ences in efficacy and safety between pivotal originator bio-
86 logic trials and biosimilar trials in RA and PsO.
87 2 Methods
88 A systematic literature review (SLR) was conducted to
89 obtain comprehensive, up-to-date data on the efficacy and
90 safety of biosimilars of adalimumab, etanercept, and
91 infliximab in the treatment of adults with RA and PsO. This
92 SLR included randomized clinical trials where patients
93 were treated with the originator biologics adalimumab,
94 etanercept, and infliximab, and their biosimilars ABP 501
95 (Amjevita), SB5, M923, MSB 11022, GP2017, CHS-1420,
96 CT-P17, SB4 (Benepali), GP2015 (Erelzi), CHS-0214, CT-
97 P05, CT-P13 (Remsima or Inflectra), SB2 (Flixabi), and
98 GP1111. Pivotal studies were head-to-head comparisons
99 between originator and placebo. Study outcomes were
100 efficacy (American College of Rheumatology [ACR] 20/50/
101 70% response rates, Disease Activity Score in 28 joints
102 [DAS28], Psoriasis Area Severity Index [PASI] 50/75/90%
103 response rates) and safety (adverse events [AEs], serious
104 AEs [SAEs], and anti-drug antibodies [ADAbs]).
105 This SLR was conducted using a standardized, thor-
106 ough, and transparent approach following Cochrane dual-
107 reviewer methodology [20]. The SLR protocol followed
108 the Preferred Reporting Items for Systematic Reviews and
109 Meta-Analyses protocol (PRISMA-P) guidelines [21]. All
110 processes and methodologies used to conduct this SLR are
111 described fully in the Electronic Supplementary Material
112 (ESM).
1133 Results
1143.1 Search and Screening
115The initial list of 351 publications was screened on
116December 7, 2016. After removing duplicates, 265 titles
117and abstracts were screened for relevance; 146 references
118underwent full-text screening and 83 references were
119quality assessed and retained for full data extraction
120(Fig. 1). Most references were of excellent or good quality
121(Supplementary Tables 1 and 2, see ESM). Of the 83
122publications, 34 and 16 reported on originator trials in RA
123and PsO, respectively, and 29 and 6 on biosimilar trials in
124those conditions. Two publications contained data for both
125RA and PsO. Biologic pivotal trials were identified through
126screening of systematic reviews.
127Of the 83 selected publications, only those that
128reported on studies in disease-modifying anti-rheumatic
129drug (DMARD)-experienced patients who were treated
130with the same biologic dosages and assessed at the same
131time points were selected for final analysis (N = 16: RA
132originators, n = 5; RA biosimilars, n = 6; PsO originators,
133n = 2; PsO biosimilars, n = 3). Studies of adalimumab
134and infliximab biosimilars in PsO did not report sufficient
135efficacy data and were not included. For RA, two pivotal
136originator studies were identified for adalimumab
137[13, 14], and one each for etanercept [15] and infliximab
138[16, 17]. One pivotal originator PsO study was identified
139for etanercept [18] and one for adalimumab [19]. All
140pivotal studies demonstrated efficacy of active treatment
141versus placebo (statistically significantly higher ACR and
142PASI response rates for RA and PsO studies, respectively
143[13–19]).
1443.2 Baseline Characteristics
145Compared with the pivotal originator studies [13–19],
146biosimilar studies had larger sample sizes, included
147patients with a shorter disease duration, and were con-
148ducted in a wider range of countries [4–12] (Supplemen-
149tary Table 3, see ESM). Beyond that, baseline patient
150characteristics were similar across the studies, with the
151following exceptions: in the RA study of SB4 (etanercept
152biosimilar) [6], mean patient age was higher and mean
153disease duration was shorter compared with the pivotal
154etanercept study [15]; in the RA study of SB2 (infliximab
155biosimilar) [8], mean disease duration was shorter and
156mean values for tender joint count (TJC) and swollen joint
157count (SJC) were lower than in the pivotal infliximab
158originator study [16, 17]. In most studies, there was not
159enough information to assess baseline differences in
160DAS28, TJC, or SJC.
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161 3.3 Efficacy Outcomes
162 In the biosimilar studies, ACR20 response rates for both
163 the originator and the biosimilar were numerically higher
164 than those in the pivotal originator studies for all treat-
165 ments. The same trend was observed for ACR50 and
166 ACR70 in the etanercept biosimilar studies, and for ACR70
167 in the infliximab studies (Table 1), but there were excep-
168 tions. The two pivotal studies of adalimumab had very
169 different ACR50 response rates (39% [13] and 55% [14]).
170 The ABP 501 biosimilar study [4] had adalimumab/
171 biosimilar ACR50 response rates similar to the Weinblatt
172pivotal study [14], but the SB5 biosimilar study [5] had
173adalimumab/biosimilar ACR50 response rates that more
174closely resembled the Keystone pivotal study [13]
175(Table 1). The pivotal study ACR70 response rates were
176more similar to each other than was seen for ACR50
177[13, 14], and the ACR70 response rates for the adali-
178mumab/biosimilar studies closely resembled these (ranging
179from 19 to 26%, Table 1). The ACR50 response rate for
180infliximab in the SB2 [8] and CT-P13 [9] biosimilar studies
181was lower than that seen in the pivotal originator study
182[16, 17], but the response rates for the biosimilars were
183higher (Table 1).
Titles screened from database (n = 132)
Titles screened from SLRs/hand search (n = 178)
Titles screened from conferences (n = 41) 
Level 1 screen from database (n = 122)
Level 1 screen from SLRs/hand search (n = 103)
Level 1 screen from conferences (n = 40) 
Level 2 screen from database (n = 40)
Level 2 screen from SLRs/hand search (n = 66)
Level 2 screen from conferences (n = 40) 
Included studies (n = 83)
• Identified from database level 2 screen (n = 14)
• Identified from SLRs/hand search (n = 52)
• Identified from conferences (n = 17)
Excluded:
• Duplicates from database (n = 10)
• Duplicates from SLRs/hand search (n = 75)
• Duplicates from conferences (n = 1)
Excluded after level 1 (relevance) screening:
• From database (n = 82)
• From SLRs/hand search (n = 35)
Excluded after level 2 (full-text) screening:
• Duplicate publication (n = 18)
• Not population of interest (n = 14)
• Not study design of interest (n = 12)
• Not comparator of interest (n = 9)
• Not outcome of interest (n = 6)
• Not randomized (n = 3)
• Not treatment of interest (n = 1)
Originators – RA
n = 34
Biosimilars – RAa
n = 29
Originators – PsO
n = 16
Biosimilars – PsOa
n = 6
Studies included in final analysis (N = 16)b
Originators – RA
n = 5
Biosimilars – RA
n = 6
Originators – PsO
n = 2
Biosimilars – PsO
n = 3
Fig. 1 Flow of papers screened and retained in the SLR. DMARD
disease-modifying anti-rheumatic drug, PsO plaque psoriasis, RA
rheumatoid arthritis, SLR systematic literature review. aTwo abstracts
contained data for both RA and PsO. bOnly those publications that
reported on studies in DMARD-experienced patients who were
treated with the same biologic dosages and assessed at the same time
points were selected for final analysis
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184 In the only PsO study assessed, the PASI75 response
185 rates at 12 weeks for etanercept (72%) and GP2015 (70%)
186 in the biosimilar study [10] were greater than the corre-
187 sponding rate for etanercept in the pivotal originator study
188 (49%) [18].
189 3.4 Safety Outcomes
190 There were no comparable safety outcomes for pivotal
191 originator and biosimilar studies of adalimumab in RA. In
192 the two head-to-head studies of etanercept versus the
193 biosimilars SB4 [6] and CHS-0214 [7], the occurrence of
194 ADAbs following treatment with etanercept was higher
195 than the occurrence of ADAbs in the pivotal etanercept
196 study [15]; the opposite was the case with ADAb occur-
197 rence for either biosimilar (Supplementary Table 4a, see
198 ESM). The occurrence of injection site reactions (ISRs)
199 was lower for etanercept and SB4 in the biosimilar study
200 [6] than for etanercept in the pivotal study [15], which was
201 also observed for etanercept and CHS-0214 [7, 15]. In the
202 head-to-head study of infliximab versus SB2 [8], the
203 occurrence of SAEs was similar between both the inflix-
204 imab and SB2 arms in the biosimilar study [8] and the
205 infliximab arm in the pivotal originator infliximab study
206 [16, 17]. The percentage of patients with a skin rash was
207lower in the SB2 [8] and CT-P13 [9] biosimilar studies
208than in the pivotal originator infliximab study [16, 17]
209(Supplementary Table 4b, see ESM).
210There were no comparable safety outcomes for pivotal
211originator and biosimilar studies of infliximab in PsO. In
212the only PsO study of adalimumab versus the biosimilar
213ABP 501 [12], the percentage of patients with SAEs was
214higher for both adalimumab (5.1%) and ABP 501 (4.6%)
215than for adalimumab (1.8%) in the pivotal originator study
216[19]. The occurrence of ISRs with adalimumab in the
217biosimilar study was higher than that observed in the piv-
218otal originator study of adalimumab (5.2 versus 3.2%) but
219lower with ABP 501 (1.7%) (Supplementary Table 4c, see
220ESM). In the only PsO study of etanercept versus the
221biosimilar GP2015, ISRs were reported in fewer etaner-
222cept-treated (14.2%) and GP2015-treated patients (4.9%) in
223the biosimilar study [10] compared with etanercept-treated
224patients (18.0%) in the pivotal originator study [18] (Sup-
225plementary Table 4d, see ESM).
2264 Discussion
227This SLR of pivotal originator biologic trials versus head-
228to-head trials of originator biologics and biosimilars indi-
229cates, as expected, an overall similarity in baseline char-
230acteristics between the two types of studies, yet identifies
231some differences in responses to treatment.
232This SLR did not establish any major differences in the
233baseline characteristics of the patients in the pivotal orig-
234inator versus biosimilar trials other than disease duration,
235which was lower for the RA biosimilar trials than the
236pivotal trials (where reported). However, it should be noted
237that this analysis was based on publicly available infor-
238mation only (additional clinical information is available in
239the European public assessment reports and FDA reports)
240and that there may have been between-trial differences that
241could not be identified. For example, biosimilar trials ten-
242ded to recruit patients from a wider range of countries than
243pivotal originator trials [22], which may have resulted in
244study population differences that were not captured using
245standard baseline parameters (such as genetic variations
246affecting drug metabolism or cultural attitudes to medica-
247tion) but might affect study results. Additionally, patient
248status in the two trial groups was arguably different
249because of the decades of additional research on both
250treatments and treatment strategies that patients in the
251biosimilar studies benefited from. Patients in the pivotal
252originator studies had access to lower-quality treatment and
253fewer treatment options before commencing biological
254therapy.
255This systematic review showed that ACR20 and PASI75
256response rates were higher in biosimilar studies compared
Table 1 Comparison of ACR response rates in pivotal versus
biosimilar studies in patients with RA
ACR20 ACR50 ACR70
Response at 24 weeks: ADA vs biosimilars
ADA from pivotal study 1 [13] 63 39 21
ADA from pivotal study 2 [14] 67 55 27
ADA from ABP 501 study [4] 72 52 23
ABP 501 [4] 75 49 26
ADA from SB5 study [5] 72 40 20
SB5 [5] 73 38 19
Response at 24 weeks: ETN vs biosimilars
ETN from pivotal study [15] 71 39 15
ETN from SB4 study [6] 80 42 23
SB4 [6] 78 47 26
ETN from CHS-0214 study [7] 91 64 38
CHS-0214 [7] 91 68 38
Response at 30 weeks: INF vs biosimilars
INF from pivotal study [16, 17] 50 27 8
INF from SB2 study [8] 59 16 17
SB2 [8] 56 31 16
INF from CT-P13 study [9] 59 17 16
CT-P13 [9] 61 35 34
ACR American College of Rheumatology, ADA adalimumab, ETN
etanercept, INF infliximab, RA rheumatoid arthritis
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257 with pivotal originator studies. This was also observed in a
258 recently published study of the etanercept biosimilar
259 GP2015, where ACR20 response at week 24 was 88.8% for
260 GP2015 and 93.6% for etanercept [23] compared with 71%
261 in the pivotal study [15]. Higher response rates in the
262 biosimilar trials could be due, at least in part, to a longer
263 disease duration in the pivotal originator trials. It is also
264 possible that the absence of a placebo arm in the biosimilar
265 studies resulted in higher expectations among patients and
266 investigators as all participants knew they were receiving
267 active treatment; it has been previously reported that using
268 active comparators only is associated with increased effect
269 sizes compared with placebo-controlled studies [24–28].
270 Indeed, ACR20/50/70 responses from open-label trials of
271 originator etanercept [29–31] more closely resemble the
272 results from the biosimilar trials reviewed here than the
273 pivotal originator etanercept trial, suggesting that the open-
274 label design can impact treatment efficacy. However, there
275 are many variations in trial design, patient population, and
276 study type between these etanercept studies and the
277 biosimilar studies that must be taken into consideration
278 when assessing the impact of open-label treatment on
279 efficacy outcomes. Other differences in trial design could
280 also contribute, each in part, to the differences seen
281 between efficacy results in different trials. Finally, bio-
282 logical differences between products in the pivotal origi-
283 nator and biosimilar trials would also contribute to the
284 differences in efficacy results seen in these studies.
285 Comparison of safety data was limited, as the available
286 data were too scarce to allow a useful comparison between
287 pivotal and biosimilar studies. Where safety outcomes
288 could be compared, the rates of ADAbs, ISRs, and skin
289 rashes were generally lower for both the originator and
290 biosimilar treatments in the biosimilar trials of RA than in
291 the pivotal originator trials (Supplementary Tables 4a, b,
292 see ESM). These discrepancies are likely to be the result of
293 many interplaying factors. For instance, the pivotal and
294 biosimilar studies often used different laboratory testing
295 methods; the pivotal studies used enzyme-linked
296 immunosorbent assays to assess ADAbs, whereas the
297 biosimilar studies used electrochemiluminescence
298 immunoassays. Since the pivotal studies were conducted,
299 improvements have been made in clinical techniques (such
300 as detection methods for etanercept ADAbs) and updates
301 made to MedDRA coding. ADAb monitoring has become
302 more rigorous; in the biosimilar trials, monitoring was
303 carried out throughout the trial, whereas in the pivotal trials
304 it was carried out on Day 1 and at study end only. Patients
305 may be more comfortable with products after 10–20 years
306 of commercial use, meaning that they might be less likely
307 to report AEs.
308 The major limitation of this SLR was the small number
309 of studies available for comparison. The numbers of
310patients in the pivotal originator studies were also small
311compared with the biosimilar studies.
3125 Conclusion
313Although the biosimilars of biologics for inflammatory
314diseases were shown to be comparable with the originator
315products throughout the regulatory approval process, there
316are numerical differences in both efficacy and safety out-
317comes between the pivotal trials of originators and con-
318firmatory clinical trials of their respective biosimilars. The
319reasons for these differences are currently only speculative.
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